Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once ...

Biogen Inc. announced positive interim results from a Phase 1 study of salanersen (BIIB115/ION306), a novel antisense oligonucleotide for treating spinal muscular atrophy (SMA).

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results – Investigational salanersen (ION306/BIIB115) developed using novel Ionis ...